-
Gene Therapy Milestone: Elevated FIX Levels Achieved in Chinese Hemophilia B Patients
Hemophilia B (HB) is a rare but severe bleeding disorder characterized by deficient or defective Factor IX (FIX), leading to prolonged bleeding episodes and increased morbidity and mortality. Traditional treatments,…
-
ASCO-GU Interview | Dr. Xuefeng Qiu: Timely Testing and Treatment, Let mCRPC patients benefit more from PARPi precision treatment
Oncology Frontier: At this year’s conference, research and application of PARP inhibitors, particularly olaparib, in advanced prostate cancer have emerged as hot topics. Could you discuss the new data and…
-
Professor Kailin Xu : From Clinical to Scientific Questions—Entry Points for CAR-T Research | 2024 CSCO Hematology Conference
CAR-T cell therapy is currently a hot research topic in the field of hematology, but how to transform the clinical issues of CAR-T cell therapy into scientific research questions remains a challenge for many clinicians. From January 26th to 28th, 2024, the “Chinese Society of Clinical Oncology (CSCO) Leukemia Committee, Lymphoma Committee, and Myeloma Preparatory…
-
Prof. Jun Ma: Key Components for Hematologic Malignancies’ Future – Medical Administration, Pharmaceuticals, and Doctor-Patient Relations | 2024 CSCO
Amidst the waves and scenic beauty, from January 26th to 28th, the “China Society of Clinical Oncology (CSCO) Leukemia Expert Committee, Lymphoma Expert Committee, and Myeloma Preparatory Committee Working Meeting, and the 2024 CSCO Hematology, Lymphoma, and Myeloma Disease Academic Conference” was grandly held in the beautiful city of Haikou. Renowned experts and scholars from…
-
Professor Aichun Liu: Stratified Treatment and Novel Drugs Resurrect Hope for Relapsed/Refractory B-Cell Lymphoma at the 2024 CSCO Hematology
In the era of medical innovation, various targeted and immune drugs are emerging, leading to breakthroughs in lymphoma treatment. From January 26th to 28th, 2024, the “Chinese Society of Clinical Oncology (CSCO) Leukemia Expert Committee, Lymphoma Expert Committee, and Myeloma Preparatory Committee Working Meeting, as well as the 2024 CSCO Hematology and Lymphoma, and Myeloma…
-
Professor Hui Wei: Mutual learning and progress, new treatment strategies and future directions in the field of leukemia | 2024 CSCO
With the rapid development of targeted therapy and immunotherapy, the field of leukemia treatment has undergone revolutionary changes. At the recently held “Chinese Society of Clinical Oncology (CSCO) Leukemia Expert Committee, Lymphoma Expert Committee, and Myeloma Preparatory Committee Working Meeting and the 2024 CSCO Hematology, Lymphoma, and Myeloma Disease Academic Conference,” domestic and international experts,…
-
ASCO-GU Interview | Dr. Tao Xu: Current status of precision treatment of prostate cancer and application of genetic testing
Oncology Frontier : With the ongoing of molecular research, the treatment of tumors has entered the era of precision medicine. At this ASCO-GU conference, we observed the release of data…
-
Professor DeHui Zou : Progress and Considerations in CAR-T Therapy for Diffuse Large B-Cell Lymphoma | 2024 CSCO Hematology Academic Conference
With unceasing exploration, the grand event took place as scheduled. From January 26 to 28, 2024, the “Chinese Society of Clinical Oncology (CSCO) Leukemia Committee, Lymphoma Committee, and Myeloma Committee Work Meeting and the 2024 CSCO Academic Conference on Hematology, Lymphoma, and Myeloma” was grandly held in the beautiful city of Haikou. Renowned experts and…
Connecting Medical Expertise through Media